5-氟尿嘧啶/明胶纳米载药微球的制备及体外性能研究

目的：以5-氟尿嘧啶(5-FU)为模型药物,明胶为载体材料,制备5-氟尿嘧啶/明胶纳米载药微球,探究药物的缓释效果和抗肿瘤性能。方法：“单凝聚相法”制备明胶纳米载药微球;透射电镜（TEM）和粒径分析仪（DLS）分析纳米微球的形貌、粒径分布情况;计算其包封率和载药量,并对其体外缓释效果和抗肿瘤性能进行研究。结果：明胶纳米微球的表面形态良好,分散均一,平均粒径65.1?2.1 nm,明胶纳米微球的包封率为23.5?1.9 %,载药量为69.7?0.5 %;明胶微球具有良好的缓释性能,Higuchi方程对微球的体外药物释放情况拟合度较高。四甲基偶氮唑蓝实验结果表明,5-FU/明胶微球对胃癌细胞(SGC7901)具有明显的抑制作用。结论：5-FU/明胶微球缓释性好,抗肿瘤活性显著,可作为抗癌药物的缓释制剂。     

羧甲基壳聚糖-蓖麻油基聚氨酯农药缓释微球的制备及性能

以羧甲基壳聚糖（CMCS）、蓖麻油（CO）和异佛尔酮二异氰酸酯（IPDI）为原料,自乳化法制备了羧甲基壳聚糖-蓖麻油基聚氨酯微球（CO-CMCS-PU）,通过分子自组装法负载阿维菌素（AVM）得到载药微球（CO-CMCS-PU@AVM）。采用FTIR、1HNMR、SEM、TGA等对产品结构及形貌进行表征,并探究了不同药量载药微球的包封率、缓释性能、抗紫外性能、叶面接触角和黏附性能。结果表明,相比AVM分散液,紫外照射后载药微球中AVM的保留率提高到43%,说明CO-CMCS-PU载体的抗紫外性能良好;载药微球比AVM分散液在黄瓜叶面上的接触角降低了20%以上,滞留量提高了40%以上,说明其在叶面上有较好的黏附性和润湿性;载药微球包封率可达80%以上,具有良好的缓释和pH响应释放性能,释药行为符合First-order动力学模型,药物释放受Fickian扩散控制。     

大蒜素/海藻酸钠/明胶/壳聚糖复合微球的制备及性能

以大蒜素为模型药物,采用复凝聚法制备了海藻酸钠/明胶/壳聚糖复合微球,考察了不同条件对微球溶胀性、载药性能和缓释性能等指标的影响。结果表明,明胶和海藻酸钠(质量比为1∶3)为2%,大蒜素投入量与混合胶比为1∶2时,制备的载药微球(DSGCM)外形规则,粒径分布在0.8~0.9mm之间,载药量为24.3%,包封率为69.4%,复合微球具有p H敏感性,在p H=7.4介质中微球溶胀率达到450%,药物释放过程符合Higuchi方程,明胶的加入可以延缓DSGCM复合微球的药物释放性能。     

非诺贝特聚合物缓释微球的制备及体外实验研究

目的制备可生物降解的具有降血脂作用的非诺贝特聚合物载药微球。方法通过复乳溶剂-挥发法制备非诺贝特缓释微球,表征其形态、粒径,并计算其载药量、包封率:用磷酸盐7.4的磷酸盐缓冲液在37℃溶解微球,并在不同的时间段在286 nm处测得其峰面积,绘制保准曲线,计算累计释放量。通过红外和差示热量扫描法显示其药物化学结构未发生改变。结果微球表面形貌光滑、完整,粒径分布均匀,平均粒径在1μm呈正态分布较好,其包封率在(89.46±0.54)%,载药量为(18.39±0.48)%,随着微球的降解,其缓释作用可以持续12天。结论通过复乳-溶剂挥发法制备的载非诺贝特PLGA缓释微球形态规整,分散性良好,并且能在12天内实现缓控释放。     

超临界流体技术制备辛伐他汀/PLLA-PEG缓释复合微球

采用超临界流体(SCF)技术制备具有缓释效果的辛伐他汀/左旋聚乳酸(PLLA)-聚乙二醇(PEG)复合微球,以载药量和粒径为指标考察了结晶压力、结晶温度以及辅料浓度等操作参数对复合微球的影响。由单因素实验得到较优工艺条件为:结晶压力12 MPa,结晶温度45℃,PEG浓度6 mg?mL?1。在此工艺条件下制备得到的复合微球载药量为12.65%,粒径为6.24μm;通过红外(IR)、差示扫描量热法(DSC)以及扫描电镜(SEM)分析表明辛伐他汀可能与PLLA形成氢键结合,并以无定型形式复合于微球中;PEG均匀复合于微球骨架中。体外溶出实验表明辛伐他汀/PLLA-PEG缓释微球具有良好的缓释效果。实验结果表明,采用SCF技术可制备得到辛伐他汀/PLLA-PEG缓释微球,添加适量PEG可有效增加载药量,提高药物溶出速率。     

明胶微球载药及其体外释放性能研究

以阿司匹林为药物模型分子,制备了载阿司匹林明胶微球。SEM研究表明,明胶微球在载药后,表面结构变得更为紧实。载药性能探讨表明,当阿司匹林的投药量为16mg时,明胶微球的载药性能较优（载药量为7．3％,包封率为57．5％）。对明胶微球在人工体液中的释药性能研究显示,载阿司匹林明胶微球具有良好的缓释性能。由于具有较大的酸性和胃蛋白酶的存在,微球在人工胃液中药物释放效率较高,在人工胃液和人工肠液中药物的释放率分别为40％和28％,且一级动力学模型对微球的体外药物释放情况拟合度较高。     

CS／PLLA／TPP纳米微胶囊的制备及体外释放

主要考察负载雷帕霉素（Rapaymcin,RAPA）的壳聚糖（Chitosan,CS）微球在加入左旋聚乳酸（L—polylactic acid,PLLA）时的载药量,包封率及在不同溶剂中的缓释性能。采用三聚磷酸钠（Sodium tripolyphosphate,TPP）作为离子交联剂,应用离子凝聚法制备CS／PLLA／TPP纳米微胶囊,用透射电镜和粒径分析仪进行了表征。结果表明：离子凝胶法可以得到粒径约300—400nm均匀分散的壳聚糖纳米微胶囊;微胶囊包封率可达84．25％,微胶囊载药量可达30．22％,雷帕霉素在不同溶剂中的缓释性能有很大不同。     

壳聚糖聚乙烯醇复合载药微球的制备

以壳聚糖(CS)为基质,通过聚乙烯醇(PVA)的引入制备壳聚糖聚乙烯醇复合载体可以分别采用室温和高温酸催化反应两种方法制备出释药性能和结构形态不同的两种复合载药微球Ⅰ和Ⅱ。其中壳聚糖/聚乙烯醇复合载药微球Ⅰ的制备工艺是调节壳聚糖和聚乙烯醇质量比6/5,复合微球Ⅰ的平均粒径1～20μm,载药量13%,LVFX体外12h累积释放80%。而壳聚糖/聚乙烯醇复合载药微球Ⅱ的平均粒径1.69μm,载药量17.1%,LVFX体外6hr基本完全释放。     

毒死蜱/壳聚糖改性凹凸棒土/海藻酸钠微球的制备与缓释性能

采用接枝方法制备了壳聚糖改性凹凸棒土,利用外源挤出法制备了毒死蜱/壳聚糖改性凹凸棒土/海藻酸钠复合微球,利用红外、热重分析和X射线衍射对改性凹凸棒土的结构进行了表征,并研究了改性凹凸棒土对载药微球的载药率、包封率、溶胀性能及缓释性能的影响。结果表明,毒死蜱仍以结晶态存在于复合微球中;壳聚糖改性凹凸棒土复合微球的载药量和包封率均高于相应的酸化凹凸棒土复合微球;加入凹凸棒土降低了载药微球的溶胀率、提高了微球的缓释性能,且壳聚糖改性凹凸棒土在抑制微球溶胀和增强缓释方面优于酸化凹凸棒土;载药微球的释药行为可用HIGUCHI动力学模型来描述。     

美洛昔康PLA缓释微球的制备及性能研究

以生物可降解材料聚乳酸(PLA)作为载体,聚乙烯醇为分散剂,二氯甲烷为溶剂,采用乳化-溶剂挥发法制备美洛昔康(Meloxicam)聚乳酸缓释微球。用生物显微镜和扫描电子显微镜观察微球形态,用傅里叶红外光谱仪检测美洛昔康是否已存在于微球中,用紫外-可见分光光度计测定了微球的包封率、载药量及其体外释药特性。结果表明:美洛昔康聚乳酸缓释微球光滑圆整,聚乳酸和美洛昔康能够有机地结合为一体,微球载药量为12.72%,包封率为89.04%,美洛昔康/PLA微球体外释放80 h后累积释药率达70%以上,具有显著的缓释作用。     

壳聚糖季铵盐表面修饰对载紫杉醇PLGA微球体外药效学的影响

采用聚(乳酸-羟基乙酸)共聚物(PLGA)纳微球装载紫杉醇,并用壳聚糖季铵盐(HTCC)对PLGA微球表面进行镀层修饰,比较了修饰前后载药微球的形貌、粒径、电位、载药率、释药行为和细胞杀伤效果. 结果表明,修饰后微球表面圆整光滑,平均粒径为882 nm,载药率可达5.15%,包埋率达70.46%,体外释药22 d累积释药率为70.17%,与修饰前没有显著性差异;但修饰后微球表面电荷由修饰前的-14.8 mV翻转为+36.7 mV,肿瘤细胞对PLGA和HTCC-PLGA载药微球的内吞量分别是Taxol?的5.6和9.7倍,且HTCC-PLGA载药微球对细胞杀伤效果显著,是一种有潜力的难溶性药物递送系统.     

Fabrication and structural regulation of PLLA porous microspheres via phase inversion emulsion and thermally induced phase separation techniques

In this work, a facile, scalable technique was developed to produce biodegradable porous microspheres by combining an oil‐in‐oil (O/O) surfactant‐free phase inversion emulsion technique with thermally induced phase separation (TIPS) method. The effects of PLLA concentration, stirring speed, macromolecule weight, and organic solvents on the size and microstructure of microspheres were investigated by scanning electron microscopy (SEM). The results revealed a highly porous structured microsphere with controllable sizes and morphologies by tuning the synthesis conditions. The typical resulting PLLA microspheres consist of nanoscale topographic structured surface and highly microporous interior. The coarse nanotopography and microcellular inner structure lead to a high drug loading capacity up to 60% for the PLLA microspheres from THF. The cumulative release percentage of the ibuprofen could reach 80% for drug‐loaded microspheres with different microstructures. The fabricated PLLA microspheres would have potential applications in the field of drug delivery and tissue engineering. © 2017 Wiley Periodicals, Inc. J. Appl. Polym. Sci. 2017 , 134, 44885.     

Preparation and evaluation of poly(3‐hydroxybutyrate) microspheres containing bovine serum albumin for controlled release

The utility of the Poly(3‐hydroxybutyrate) (PHB) to encapsulate and control the release of bovine serum albumin (BSA), via microspheres, was investigated. Various preparing parameters, including polymer concentration in oil phase, emulsification concentration in external water phase, volume ratio of inner water phase to oil phase, and volume ratio of primary emulsion to external water phase were altered during the microspheres production. The effects of these changes on the morphological characteristics of the microspheres, size of the microspheres, drug loading, encapsulation efficiency, and drug release rates were examined. The diameter of the microspheres ranged from 6.9 to 20.3 μm and showed different degrees of porous structure depending on the different preparation parameters. The maximum and minimum BSA encapsulation efficiency within the polymeric microspheres were 69.8 and 7.5%, respectively, varying with preparation conditions. The controlled release characteristics of the microspheres for BSA were investigated in pH 7.4 media. The initial BSA burst release from 8.9 to 63.1% followed by constant slow release for 28 days was observed for BSA from BSA‐loaded microspheres and followed the Higuchi matrix model. So, the release behavior of microspheres showed the feasibility of BSA‐loaded microspheres as controlled release devices. Pristine BSA, pristine PHB microspheres, and BSA‐loaded microspheres were analyzed by Fourier transform infrared spectrophotometer, which indicated no interaction between BSA and PHB. Differential scanning calorimetry on BSA‐loaded microspheres indicated a molecular level dispersion of BSA in the microspheres. © 2008 Wiley Periodicals, Inc. J Appl Polym Sci, 2008     

复相乳化法制备海藻酸钙微球及其释放行为

采用复相乳化法制备了载牛血清白蛋白(BSA)的海藻酸钙微球,通过正交实验和单因素分析,以BSA包埋率、微球的载药率和平均粒径为考察指标,优化了该方法的制备参数,使最终制备的微球平均粒径小于10 mm,球形度较好,包埋率约70%,载药率达4%. 随着海藻酸钠质量分数的降低和BSA质量的增大,微球的包埋率下降、载药率升高、平均粒径减小. 微囊化BSA的体外释放曲线表明,该系统存在pH响应特性,尤其在磷酸缓冲液中,被包埋BSA的释放速率较快. 电泳结果表明,BSA的分子结构并未受制备过程的影响. 因此,该微囊化方法有望用于蛋白类药物的控释制剂,使其免受胃酸等的破坏,达到肠部释药的目的.     

Enhanced gastric retention and drug release via development of novel floating microspheres based on Eudragit E100 and polycaprolactone: synthesis and in vitro evaluation

Eudragit E 100 and polycaprolactone (PCL) floating microspheres for enhanced gastric retention and drug release were successfully prepared by oil in water solvent evaporation method. Metronidazole benzoate, an anti-protozoal drug, was used as a model drug. Polyvinyl alcohol was used as an emulsifier. The prepared microspheres were observed for % recovery, % degree of hydration, % water uptake, % drug loading, % buoyancy and % drug release. The physico-chemical properties of the microspheres were studied by calculating encapsulation efficiency of microspheres and drug release kinetics. Drug release characteristics of microspheres were studied in simulated gastric fluid and simulated intestinal fluid i.e., at pH 1.2 and 7.4 respectively. Fourier transform infrared spectroscopy was used to reveal the chemical interaction between drug and polymers. Scanning electron microscopy was conducted to study the morphology of the synthesized microspheres.     

Effects of the process parameters on the initial burst release of poly(lactide‐co‐glycolide) microspheres containing bovine serum albumin by the double‐emulsion solvent evaporation/extraction method

The effects of fabrication parameters on the morphology, drug loading, and initial burst release of poly(lactide‐co‐glycolide) microspheres loaded with bovine serum albumin were investigated to establish an optimal process and system for the in vivo delivery of therapeutic proteins. Through the addition of salts or sugars to induce an osmotic pressure in the external water phase, large microspheres were seen to have their morphology, drug loading, and initial burst release significantly affected. However, the effect was not observed for compact microspheres less than 10 μm in diameter. The presence of poly(vinyl alcohol), Pluronic F127, and Tween 80 in the internal water phase had detrimental effects on the drug loading because of the depressed stability of the primary emulsion and competitive interactions of surface‐active substances with the polymer. However, the simultaneous addition of salts to the external water phase resulted in enhanced drug loading and decreased initial burst. The polymer concentration and volume of the internal water phase were important factors influencing the characteristics of the microspheres. These parameters were optimized for achieving the maximal drug loading and a low initial burst. The solvent extraction method yielded microspheres with a higher drug loading and a lower initial burst in comparison with the solvent evaporation method. Different ranges of protein encapsulation efficiencies were obtained with blends of poly(lactide‐co‐glycolide) and poly(ethylene glycol), depending on the molecular weight and content of poly(ethylene glycol). © 2009 Wiley Periodicals, Inc. J Appl Polym Sci, 2010     

Preparation and in vitro release behavior of urapidil hydrochloride loading into microspheres based on poly(L‐lactide)

Microencapsulation of the antihypertensive drug urapidil hydrochloride was investigated as a means of controlling drug release and minimizing or eliminating local side effects. Poly(L ‐lactide) (PLLA) microspheres were prepared using an alternative oil‐in‐water (O/W) solvent‐evaporation method such as the O/W cosolvent solvent‐evaporation method and O/W with various electrolytes added to the aqueous phase method. The surface morphology and the size of the microspheres were observed by scanning electron microscope. Meanwhile, the drug loading efficiency of microspheres and the in vitro release of urapidil hydrochloride from microspheres were performed. The release study indicated that the urapidil hydrochloride‐PLLA microspheres exhibited better sustained release capacity, and the kinetics of urapidil hydrochloride‐PLLA microspheres in vitro release could be described by the Higuchi equation. © 2009 Wiley Periodicals, Inc. J Appl Polym Sci, 2010     

Synthesis and characterization of star‐shaped PLLA with sorbitol as core and its microspheres application in controlled drug release

The purpose of this study was to investigate the suitability of a six‐arm star‐shaped poly(l ‐lactide)s (s‐PLLA) as controlled drug carriers for hydrophobic drug molecules. First, s‐PLLA was synthesized by ring‐opening polymerization of l ‐lactide using sorbitol as initiator and stannous octoate as catalyst. The structure and molecular weight (M_w) of s‐PLLA was characterized with ¹H NMR, ¹³C NMR, and GPC. Second, rifampicin (RIF) used as a model drug was encapsulated within the microspheres of s‐PLLA via oil‐in‐water emulsion/solvent evaporation technique. The morphology, drug encapsulation efficiency (EE), and in vitro release behavior of the prepared microspheres were studied in details. Results indicated that the average diameters of s‐PLLA microspheres can be controlled between 8 and 20 µm by varying the copolymer's concentration or M_w . The EE of RIF was mainly determined by the concentration of s‐PLLA. The in vitro study showed that the burst release behavior can be depressed by increasing the M_w of the s‐PLLA. Present work suggests that the synthesized s‐PLLA could be used as a new material for drug delivery. © 2015 Wiley Periodicals, Inc. J. Appl. Polym. Sci. 2015 , 132, 42213.     

Biodegradable polymeric microspheres of gelatin and carboxymethyl guar gum for controlled release of theophylline

Carboxymethyl guar gum (CMGG) was synthesized by carboxymethylation of guar gum (GG), which was blended with gelatin (GE) to obtain a novel semi-interpenetrating polymer network (semi-IPN) in the form of microspheres prepared by water-in-oil emulsion method to investigate the controlled release of theophylline (THP), an antiasthmatic drug. Electronic spectroscopy revealed the drug encapsulation ranging from 56 to 74 %. Fourier Transform infrared spectroscopy confirmed the carboxymethylation of GG as well as the semi-IPN structure of the blend polymer. Scanning electron microscopy indicated the smooth surfaces with spherical microspheres. Differential scanning calorimetric and X-ray diffraction studies showed the molecular level dispersion of drug in the microspheres. The in vitro drug release profiles were analyzed to study the effect of polymer blend composition, % drug loading and amount of glutaraldehyde added as a crosslinker. The drug release was extended up to 26 h. The in vitro release data performed in acidic and alkaline media were analyzed using the empirical equations to understand the release profiles of THP.